UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.
Dec 15, 2014
0
0
Researchers at Kanazawa University report in Nature Communications that AXL, a protein belonging to the class of receptor tyrosine kinases, causes some lung cancer patients to have an intrinsic resistance to the drug osimertinib. ...
Feb 26, 2019
0
0
A team of researchers has uncovered the identity of off-target cells responsible for abnormal outgrowth and devised a method to eliminate them from iPS cell-derived pancreatic tissues in development for cell therapy against ...
May 13, 2024
0
58
Lupus, a chronic autoimmune disease, can wreak havoc on an affected individual's body through inflammation, pain and even damage of the skin, joints and organs.
Dec 16, 2016
0
38
Researchers have shown for the first time that a crucial interface in a protein that drives cancer growth could act as a target for more effective treatments.
Mar 19, 2024
0
47
Erxi Wu, assistant professor of pharmaceutical sciences, and Shuang Zhou, doctoral student of pharmaceutical sciences in Wu’s lab, co-wrote the article, "High glucose promotes pancreatic cancer cell proliferation via ...
Nov 15, 2011
0
0
Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each ...
Jun 2, 2011
0
0
(HealthDay)—Semiquantitative immunohistochemical expression of progesterone receptor-positive tumor cells improves prediction of survival within luminal A breast cancers, according to a study published online Dec. 10 in ...
Dec 17, 2012
0
0
Lung tumors called adenocarcinomas sometimes respond to initially effective treatments by transforming into a much more aggressive small cell lung cancer (SCLC) that spreads rapidly and has few options for treatment. Researchers ...
Feb 8, 2024
0
10
Drugs introduced more than a decade ago that target mutations in a protein known as the epidermal growth factor receptor (EGFR) held the promise of personalized treatments for a common form of non-small cell lung cancer. ...
May 20, 2015
0
33
